Pharmacokinetic models for propofol-defining and illuminating the devil in the detail by Absalom, A.R. et al.
Pharmacokinetic models for propofol—defining and illuminating
the devil in the detail
A. R. Absalom1*, V. Mani2, T. De Smet3 and M. M. R. F. Struys4
1University Division of Anaesthesia, Addenbrookes Hospital, Cambridge CB2 2QQ, UK. 2Royal Hospital for
Sick Children, Dalnair Street, Glasgow G3 8SJ, UK. 3BVBA Demed, Hollebeek 145 B-9140, Temse, Belgium.
4Department of Anaesthesia, University Medical Center Groningen, University of Groningen, Hanzeplein 1,
9713 GZ Groningen, The Netherlands
*Corresponding author. E-mail: ara30@wbic.cam.ac.uk
The recently introduced open-target-controlled infusion (TCI) systems can be programmed
with any pharmacokinetic model, and allow either plasma- or effect-site targeting. With effect-
site targeting the goal is to achieve a user-defined target effect-site concentration as rapidly as
possible, by manipulating the plasma concentration around the target. Currently systems are
pre-programmed with the Marsh and Schnider pharmacokinetic models for propofol. The
former is an adapted version of the Gepts model, in which the rate constants are fixed,
whereas compartment volumes and clearances are weight proportional. The Schnider model
was developed during combined pharmacokinetic–pharmacodynamic modelling studies. It has
fixed values for V1, V3, k13, and k31, adjusts V2, k12, and k21 for age, and adjusts k10 according
to total weight, lean body mass (LBM), and height. In plasma targeting mode, the small, fixed
V1 results in very small initial doses on starting the system or on increasing the target concen-
tration in comparison with the Marsh model. The Schnider model should thus always be used
in effect-site targeting mode, in which larger initial doses are administered, albeit still smaller
than for the Marsh model. Users of the Schnider model should be aware that in the morbidly
obese the LBM equation can generate paradoxical values resulting in excessive increases in
maintenance infusion rates. Finally, the two currently available open TCI systems implement
different methods of effect-site targeting for the Schnider model, and in a small subset of
patients the induction doses generated by the two methods can differ significantly.
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When TCI devices first became commercially available in
1997, the concept was new to clinicians and regulatory
authorities, many of whom feared the possible compli-
cations arising from use of a device that changed infusion
rates automatically. A strong emphasis on safety was thus
necessary to ensure regulatory approval and the confidence
of clinicians. The systems all contained the Diprifusorw
(Astra Zeneca, UK) microprocessor, programmed with the
Marsh adult pharmacokinetic model for propofol.15 The
Diprifusor contained two microprocessors—one 16 bit and
the other 8 bit (G.N.C. Kenny, personal communication),
the former to calculate and implement the required infu-
sion rates, and the latter to monitor the driving motor to
calculate the volume of propofol actually being adminis-
tered and to perform a simple calculation of the estimated
plasma concentration from this. The system was designed
to shut down if there was a significant discrepancy
between the plasma calculations estimated by the two
microprocessors.
The first generation systems only allowed the user to
target the plasma concentration. At the time of their release
the significance of an effect-site anatomically and tem-
porally separate from the plasma was only just being fully
appreciated. Early models only displayed the target and esti-
mated plasma concentrations. Later on a keo value was incor-
porated allowing an estimate of the effect-site concentration
to be made and to be displayed as additional information.
In addition to controlling the user interface, and calcu-
lating and implementing the infusion rates required to
achieve the target concentration, the Diprifusor micropro-
cessor also controlled a syringe recognition system that
only allowed the use of glass pre-filled 50 ml syringes of
1% or 2% propofol (Diprivan 1%TM or Diprivan 2%TM,
AstraZeneca, UK).
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Open TCI systems do not contain the Diprifusor
microprocessor and do not have a syringe and drug
recognition system. They contain a single processor that
the manufacturer can program with any pharmacokinetic
model for any drug, and allow the use of a wide variety of
syringes of sizes between 10 ml and 50 ml supplied by
several different manufacturers. The chief benefit of these
systems is that cheaper, generic formulations of propofol
can be used for TCI.
At the time of publication, there are two open TCI
systems commercially available: the Alaris Asena PKTM
(Cardinal Health, Alaris Products, Basingstoke, UK) and
the Base PrimeaTM (Fresenius, France). These systems
provide the user with a potentially confusing range of
choices. Generally they are supplied with pre-loaded and
activated models for remifentanil (Minto model),16 18
sufentanil,9 and two models for propofol. With the Base
Primea system the user has a choice of the modified
Marsh22 and Schnider19 20 models, whereas with the
Asena PK system, the choice is between the Marsh15 and
Schnider19 20 adult models and the Kataria paediatric
model.11 With all these drugs and models both plasma and
effect-site targeting are possible (except with the Marsh
model implemented in the Asena PK). To further add to
the confusion the two systems use two different methods
of implementing effect-site targeting with the Schnider
model.
Failure to appreciate the differences between the differ-
ent propofol models and implementation methods may
result in administration of excessive or inadequate doses
of propofol with potentially harmful results.
Plasma vs effect-site targeting
Early TCI systems were designed to achieve a user-defined
plasma ‘target concentration’. It soon became apparent
that there was hysteresis in the relationship between
plasma concentration and clinical effect, caused by the
temporal delay in equilibration between plasma concen-
trations and the concentration at the sites of action within
the central nervous system, referred to as the ‘effect-site’.
The rate of plasma/effect-site equilibration depends on
factors that determine the rate of drug delivery to the
effect-site (such as cardiac output and cerebral blood flow)
and pharmacological properties that determine the rate of
drug transfer across the blood–brain barrier (lipid solubi-
lity, degree of ionization, etc). The time course of plasma/
effect-site equilibration can be mathematically described
by a first-order rate constant typically referred to as the
keo. Strictly speaking, this term should be used to describe
the rate of removal of drug from the effect-site out of the
body, but the effect-site is regarded as having negligible
volume, so that there is no need for separate constants
describing the rate constants for movement into and out of
the effect compartment (the keo defines the proportional
change in each unit of time of the concentration gradient
between the plasma and effect-site).
With effect-site targeting, the TCI system manipulates
the plasma concentration to achieve the effect-site concen-
tration as rapidly as possible. When the effect-site target
concentration is increased, the TCI system briefly increases
the plasma concentration to an optimal level above the
target effect-site concentration before temporarily stopping
the infusion to allow the plasma concentration to decrease
to the level of the target effect-site concentration. Most
systems use mathematical iterations to determine the mag-
nitude of the optimal plasma concentration overshoot—the
peak plasma concentration that generates a gradient suffi-
cient to cause the most rapid increase in effect-site con-
centration but without an overshoot of the effect-site
concentration above its target (Fig. 1).
If the target effect-site concentration is reduced the
system stops the infusion, allowing the plasma concen-
trations to fall, thereby generating a concentration gradient
out of the effect-site, until the estimated effect-site con-
centration has fallen to the new target. At this stage the
plasma concentration will be less than the effect-site con-
centration, and so the system has to administer a small
bolus to increase the plasma concentration to the target
concentration.
With effect-site targeting, the magnitude of the plasma
concentration overshoot estimated by the system depends
critically on the keo and also on the estimated rate of
decline in the plasma concentration. If a slower (smaller)
keo is used, a greater overshoot in the peak plasma concen-
tration will be required to produce a larger concentration
gradient between the blood and the effect-site and thereby
to hasten plasma-effect-site equilibration (Fig. 2).
The estimated rate of decline of the plasma concentration
also has an influence on the overshoot. A system that esti-
mates a slower decline in plasma concentrations will
administer a lesser plasma overshoot than a system estimat-
ing a faster decline, to avoid an eventual effect-site concen-
tration overshoot. After a bolus dose, the rate of decline in
plasma concentrations mostly depends on the rate of fast
re-distribution, but is also influenced by the rate of drug
metabolism and of slow re-distribution. Naturally, the net
rate of decline caused by re-distribution depends on the
concentration gradients between compartments. If a system
estimates that the plasma drug concentration will fall
rapidly after a bolus at a given time, then a greater over-
shoot is necessary to optimize the gradient driving drug
into the effect-site, and the flux of drug into the effect-site,
than if a slow rate of decline were estimated.
Since the accuracy of the estimated plasma concentration
itself and the degree of overshoot required depend on the
accuracy of several parameters and assumptions, there are
multiple potential sources of error. Model errors resulting
in excessively high plasma concentrations may well be tol-
erated by young fit patients, but in frail, elderly subjects,
they may result in significant cardiovascular instability.
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Methods for estimating keo
Unlike isoflurane, for which the brain concentration can be
estimated with reasonable accuracy by magnetic spec-
troscopy,13 14 there are currently no methods of directly
estimating the effect-site concentrations of i.v. anaesthetic
agents. The time course of changes in effect-site concen-
tration can however be estimated by recording a measure
of clinical effect and then used to generate an estimate of
the keo. Ideally, a combined pharmacokinetic–pharmaco-
dynamic (PK/PD) modelling technique should be used, in
which concomitant measurements of plasma drug concen-
trations and clinical effect are performed in a study popu-
lation during and after administration of a bolus, an
infusion, or a combination of the two. The result is a com-
bined model that estimates plasma and effect-site
concentrations.
When pharmacodynamic and pharmacokinetic data are
not available from the same subject group, then a
model-independent parameter called ‘Time to peak effect’
(TTPE) can be used to estimate the keo for a PK model
and patient group.17 After any bolus, maximal clinical
effects will occur when the effect-site concentration
reaches its maximum. Since transfer of drug between
blood and effect-site is gradient-driven, when the plasma
concentration is greater than the effect-site concentration,
net transfer is from plasma to effect-site and vice versa.
When depicted graphically, this peak occurs when the
effect-site concentration curve crosses the plasma concen-
tration curve, reaching a local maximum. TTPE is defined
as the time delay between a bolus injection and the peak
clinical effect. It is considered to be independent of the
size of the bolus dose.
The effect-site compartment is assumed to have negli-
gible volume. Hence uptake of drug into the effect-site
should have negligible influence on the plasma concen-
tration of a drug, so that the calculated plasma concentration
profile following an infusion of drug is identical for any
value of keo. With this assumption, determination of the keo
becomes a simple one-dimensional mathematical minimiz-
ation problem. This process is illustrated in Figure 3, in
which measured or estimated plasma concentrations (fol-
lowing a bolus dose) are plotted over time alongside an
observed measure of clinical effect. Different keo values are
then used to estimate the effect-site concentration. Smaller
keo values result in the estimated peak in effect-site concen-
trations being smaller and occurring later than if faster
(larger) keo is used. In this case, a keo of 0.38 min
21 results
in a peak effect-site concentration at 100 s which matches
best with the observed maximal clinical effect.
A disadvantage of this approach is that it requires
precise observation of TTPE, whereas in real clinical situ-
ations noise and other factors make the observation of a
single ‘peak effect’ difficult. Rather than relying mainly
on one observation an alternative approach is to plot the
relationship between the measure of clinical effect and the
estimated effect-site concentrations arising from different
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Fig 1 Effect-site targeted TCI. At time zero the target is set at 3 mg ml21, at 5 min it is increased to 6 mg ml21, and at 10 min it is reduced to
3 mg ml21. At each target change the system manipulates the blood concentration to rapidly achieve the target effect-site concentration.
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Fig 2 Effect-site targeted TCI for propofol (Marsh model), showing the
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keo values (Fig. 4). Simple mathematical techniques can
then be used to determine the keo value which limits the
area within the loop caused by the hysteresis effect. In this
hypothetical example, a keo of 0.38 min
21 is selected
since it completely collapses the hysteresis curve. This
methodology can also be applied to studies involving
infusions.
Difference between Marsh and Schnider
models
These models were derived in different ways, have quite
different parameters, and when used to determine the infu-
sion rates of a TCI system during effect-site TCI, can
result in significantly different propofol infusion rates. In
normal and mildly obese patients, the differences mainly
occur within the first 10 min after a target concentration
increase (Fig. 5), whereas in more obese patients, the
differences can be greater throughout the infusion.
Marsh model
The Marsh model parameters were published with the
results of a study of its predictive performance, and that of
an adapted model, in children in 1991.15 Compartmental
volumes are proportional to weight, whereas rate constants
for slow and fast redistribution are fixed (Table 1). It was
pragmatically adapted from the Gepts three-compartmental
model,8 which was developed from a study involving three
groups of six patients who each received constant rate
infusions of propofol at either 3, 6, or 9 mg kg21 h21.
Although full details were not published it appears that the
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study included few elderly or obese patients. The Marsh
model is identical to the Gepts model in all respects
except that the central compartmental volume was
increased to 0.228 litre kg21. There is no published expla-
nation of the rationale for this adjustment.
Later on, a keo value of 0.26 min
21 came to be used
with this model in first generation TCI pumps, to enable
effect-site concentration estimations to be made. The data
on which this keo value was based were never published in
the peer-reviewed literature, although it is quite similar to
the value of 0.2 min21 found by Billard and colleagues.3
Struys and colleagues23 later published evidence that a
keo of 1.2 min
21 used in conjunction with the Marsh phar-
macokinetic parameters more accurately predicted the time
course of clinical effect (as assessed by the Bispectral
Index) than the keo of 0.26 min
21. A keo of 1.2 min
21 used
with the Marsh model results in an estimated TTPE of
approximately 1.6 min, which is consistent with the findings
of other groups.19 This combination (sometimes referred to
as the ‘modified Marsh’ model) is used in the Base Primea
TCI system, and results in more gentle manipulations of the
plasma concentration (above and below the target concen-
tration) when effect-site targeting mode is used.
Schnider model
This model was derived during a combined pharmacoki-
netic and pharmacodynamic study in a single set of 24
volunteers (11 female, 13 male; weight range 44–123 kg;
age range 25–81 yr; height range 155–196 cm).19 20 The
co-variates are total body weight, age, height, and lean
body mass (LBM) (calculated from total weight, gender,
and height) (Table 1).
V1 and V3 (and thus k13 and k31) are fixed, whereas the
size of V2 (and thus k12 and k21) is influenced only by
age, being smaller with advancing age. The implications
of this are that after a bolus of a given size, the Schnider
model will estimate that the same peak plasma concen-
tration is achieved for all patients, irrespective of their age,
height, or weight. After the peak, the initial rate of
decrease in plasma concentration will depend on the age
of the patient. This is in contrast to the Marsh model,
where estimated plasma concentrations after a given bolus
are proportional to the patient’s weight, whereas the esti-
mated rate of decline of the plasma concentration is the
same for all patients.
The elimination rate constant, k10, is the only parameter
influenced by body mass. It varies in a complex manner
with total body weight, height, and LBM but does not
vary with age. Thus, these only influence the rate at which
drug metabolism is estimated to occur, and thus the rate at
which propofol is infused to replace these losses during
the maintenance phase.
The Schnider model incorporates a keo of 0.456 min
21
derived from the combined PK/PD study mentioned
earlier, in which a rapidly calculated EEG parameter was
used as a measure of clinical effect. This keo, in conjunc-
tion with the PK parameters, predicts a TTPE, after a
bolus dose, of 1.69 min.
LBM calculation formula used in Schnider
model
In the Schnider model, LBM is calculated using the James
formula,10 which performs satisfactorily in normal and
moderately obese patients, but paradoxically in the
severely obese.
The James formula calculates LBM as follows:
Males : LBM¼1:1weight–128ðweight/heightÞ2
Females : LBM¼1:07weight–148ðweight/heightÞ2
Figure 6 illustrates the relationship between total body
weight, LBM, and ideal body mass (IBM). Note that for
males, the calculated LBM increases with total body mass
until it reaches a maximum value slightly greater than the
ideal body mass [Males: ideal body weight
(kg)¼49.9þ0.89 x (height in cm2152.4); Females: ideal
body weight (kg)¼45.4þ0.89 x (height in cm2152.4)].1
Thereafter [when the body mass index (BMI) is .42 kg
m22], with increasing total body weight, the calculated
LBM decreases paradoxically. A similar paradoxical situ-
ation exists with females. The calculated LBM increases
Table 1 Adult propofol models
Marsh15 Schnider19 20
General model 70 kg General model (LBM calculated using weight, height, gender) 70 kg, male height 170 cm
V1 0.228 litre kg21 15.9 litre 4.27 litre 4.27 litre
V2 0.463 litre kg21 32.4 litre 18.920.391(age253) litre 24.0 litre
V3 2.893 litre kg21 202.0 litre 238 litre 238 litre
k10 (min
21) 0.119 0.119 0.443+0.0107(weight277)20.0159(LBM259)+0.0062(height2177) 0.384
k12 (min
21) 0.112 0.112 0.30220.0056(age253) 0.375
k13 (min
21) 0.042 0.042 0.196 0.196
k21 (min
21) 0.055 0.055 [1.29–0.024(age253)]/[18.9–0.391(age253)] 0.067
k31 (min
21) 0.0033 0.0033 0.0035 0.004
keo (min
21) 0.26 0.26 0.456 0.456
TTPE (min) 4.5 4.5 1.69 1.69
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with total body weight, and reaches a peak when the BMI
is approximately 37 kg m22. This maximum LBM value
is slightly less than the ideal body mass (for the appropri-
ate height) except in very short females in whom it is
similar to ideal body mass.
The effect of the calculated LBM value on the k10, and
hence on maintenance infusion rates, is not immediately
obvious. As shown in Table 1, increasing total body
weight and height tend to increase the k10, whereas
increasing LBM will tend to decrease the k10. Thus, total
body weight and LBM have opposing effects on the k10,
with the LBM value moderating the influence of total
body weight on the k10. In severely obese patients, the
paradoxically low calculated LBM causes a large increase
in calculated k10. As a result, as BMI increases beyond
42 kg m22 in males, and 37 kg m22 in females, the
infusion rates required (to replace the estimated drug
metabolism) increase exponentially. The relationship
between total body weight and calculated k10 for patients
of different heights is illustrated in Figure 7 (solid lines).
The manufacturers of current open TCI systems have
implemented compromise solutions that may improve
safety. In the Asena PK system, if the user enters a body
weight and height combination that falls on the declining
portion of the total body weight (TBW) vs LBM curve,
then the maximal LBM figure for that height is used. A
similar solution in implemented in the Base Primea
system: for a given height, the system will not accept a
TBW figure that falls on the declining portion of the
curve, and the user is required to enter a total body mass
at or below the value generating the maximum LBM. The
influence of increasing total body weight on the calculated
k10, when these limits in LBM are applied in the severely
obese, are illustrated in Figure 7 (dashed lines).
The influence of total body weight on maintenance infu-
sion rates in the morbidly obese are discussed in greater
detail in what follows.
Effect-site targeting implementation with
the Schnider model
Schnider used semi-linear canonical correlation to calcu-
late the ‘canonical univariate parameter’ from EEG data
recorded from the volunteers in his study, and used this to
track the time course of the pharmacodynamic effect of
propofol.20 The median TTPE of a propofol bolus, deter-
mined by this parameter, was 1.69 min. Based on visual
inspection of the EEG the TTPE ranged from 1.0 to 2.4
min (median 1.6 min). When a TTPE of 1.6 min was used
to calculate the keo for each of their volunteers, the
median keo was 0.456 min
21. The authors concluded that
a keo of 0.456 min
21 used with the pharmacokinetic par-
ameters determined in the same group of volunteers19 pro-
vided the best description of the time course of clinical
effect of propofol.
After a standard bolus dose (e.g. 2 mg kg21), the Marsh
model estimates the same peak concentration, and the
same rate of decline in plasma concentration, in all sub-
jects, since the compartment volumes and clearances are
all weight-proportional. As a result, use of a single keo
value generates the same estimated TTPE in all patients.
The converse is also true: if a single TTPE is used, then
the calculated keo will be the same for all patients.
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The situation is different with the Schnider model.
A weight-adjusted dose will result in different estimated
peak plasma concentrations for patients of different
weight, since the volume of V1 is the same for all patients.
After the peak is reached, the rate of decline in plasma
concentrations will vary from patient-to-patient, depending
on the age, gender, height, and weight. If a fixed keo is
used to calculate the TTPE in patients who differ in one
or more of these parameters, then different TTPE values
will result. Likewise, a single TTPE value used to calcu-
late individual keo values will result in different values in
different patients. This latter approach is illustrated in
Figure 8, which shows the estimated plasma and effect-site
propofol concentrations arising after a 2 mg kg21 propofol
bolus in two different male patients, both weighing 70 kg,
but one being older and taller than the other. In this
example, the keo has been adjusted in each case to cause
the effect-site concentration to reach local maxima at
1.6 min. In the case of the elderly patient a faster (larger)
keo value is required, and results in a greater estimated
peak effect-site concentration.
The Asena PK open TCI system incorporates many of
the software routines that are used in the Rugloop II soft-
ware, developed by T.D.S. and M.M.R.F.S.7 Alternative
implementations can be found in Stanpump, developed by
Steven L. Shafer, MD at Stanford University.22 Thus, in
common with Rugloop and Stanpump, when implement-
ing effect-site targeting for the Schnider model, the Asena
PK uses a fixed time to peak approach to calculate a
unique keo for each patient. The Base Primea system on
the other hand uses a fixed keo (0.456 min
21), and this
results in different times to peak effect for different
patients.
For non-obese and mildly obese patients, fixed TTPE
approach results in a keo that is in the vicinity of 0.456
min21. For some severely obese patients this approach can
generate a significantly faster (larger) keo. As mentioned
earlier, the choice of keo will influence the degree of
plasma concentration over- and under-shoot when the
target concentration is changed, and thus also influences
the overall dose.
Practical consequences of differences between
the Marsh and Schnider models
Plasma vs effect-site targeting
In general, for non-obese or mildly obese patients, the
cumulative dose administered by the two models using
the two modes of operation will follow a similar pattern.
The highest total dose will be given by the Marsh model
in effect-site targeting mode (with a keo of 0.26 min
21),
followed by the Marsh model in plasma targeting mode,
then the Schnider model in effect-site targeting mode, and
finally the lowest dose will be administered by the
Schnider model in plasma targeting mode. Figure 5 shows
the cumulative dose administered to a 40-yr-old man, who
weighs 70 kg and is 170 cm tall, by systems implementing
the Marsh and Schnider models in effect-site and plasma
targeting mode (target concentration 4 mg ml21).
The important question is not, of course, which
model delivers the largest or smallest dose of drug, but
which one produces the most accurate predictions of
plasma and effect-site concentration. Plasma concentrations
can be measured directly offline using chromatography.
While several studies have assessed the predictive perform-
ance of the Marsh model,2 5 6 24 other than the initial study
from which the Schnider model was derived, there is a
paucity of published data of the ability of the latter model
to predict plasma propofol concentrations accurately.
There are very few situations in which use of the
Schnider model in plasma targeting mode may be rec-
ommended. When a TCI system is used in plasma target-
ing mode, and the target plasma concentration is
increased, the size of the initial bolus dose (in mg)
required to increase the plasma concentration to the new
target is calculated mathematically as follows:
Bolus dose (mg)¼ðCp;target;new–Cp;target;oldÞV1
4drug concentration in syringe
Thus the size of the initial bolus is directly proportional
to the value of V1 in the model. In the Marsh model, V1
varies with weight of the patient (15.9 litre for a 70 kg
patient), whereas in the Schnider it is fixed at 4.27 litre
irrespective of the patient’s weight. As a result, when
plasma targeting k10 mode is used with the Schnider
model, the small fixed V1 results in the same initial bolus
being given to all patients, for a given plasma target con-
centration, regardless of their age, weight or height. This
is counter-intuitive and contrary to the clinical experience
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Fig 8 Predicted blood and effect-site concentration profiles, based on the
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of anaesthetists, who observe that induction requirements
increase with body weight.
In effect-site targeting mode, a system implementing
the Schnider model calculates a plasma concentration
overshoot. The exact extent of the overshoot will depend
on the age, weight, and height of the patient, and will gen-
erally be of the order of 300% of the target concentration.
In almost all situations where the Schnider model is used,
it should be used in effect-site targeting mode.
Few would recommend the use of the Marsh model in
effect-site targeting mode with a keo of 0.26 min
21.
Although this keo value is slower (smaller) than the keo used
with the Schnider model, the degree of overshoot of the esti-
mated plasma concentration is far less than with the
Schnider model. This is because the estimated rate of
decline of plasma concentrations after a bolus is far slower
with the Marsh model than the Schnider model, resulting in
a more modest overshoot of 150%. Nonetheless, the much
larger V1 value in the Marsh model results in much greater
initial doses being administered in this mode. For example,
for an initial target concentration of 4 mg ml21, the initial
bolus will be 172 mg for a 70 kg patient, whereas for the
Schnider model the initial dose will be 77 mg.
The Base Primea system allows effect-site targeting
with the Marsh model with a faster keo value of
1.2 min21, resulting in smaller overshoots (of the order of
50%). In effect-site targeting mode at an initial target of
4 mg ml21, it will administer an initial dose of 98 mg to a
70 kg man (age 40 yr, height 170 cm).
In fit, healthy, young patients, the use of the modified
Marsh model in effect-site targeting mode may be safe and
justifiable. With currently available evidence, in almost all
other situations, the safest options, and those most com-
monly chosen by clinicians are either of the Marsh in
plasma mode or the Schnider model in effect-site mode.
Thus in the following sections, we will compare the initial
and subsequent doses administered with these two options.
Size of the initial dose on starting an infusion
Figure 9 illustrates the influence of choice of model and
implementation, total body weight and height on the
cumulative dose administered during the first 15 min of a
TCI, for males and females aged 20, 40, and 80 yr. The
target concentration is 5 mg ml21, and the figure illustrates
the doses administered by the Marsh model in plasma tar-
geting mode and the Schnider model in effect-site target-
ing mode (both fixed keo method and fixed TTPE
implementation). For the Schnider implementations, the
dotted lines indicate the doses administered if the original
LBM equations are used in the morbidly obese without the
corrections mentioned earlier.
As can be seen in the figure, the dose administered by
the Marsh model is unaffected by age or height. For the
Schnider model, increasing age decreases the dose,
whereas increasing height increases the dose, except in the
morbidly obese in whom shorter patients may sometimes
receive larger doses than taller patients of the same
weight. In shorter patients, increasing total weight causes
the dose administered to increase more steeply.
For the Marsh model (in plasma-targeting mode), the
dose administered increases linearly with total body mass,
and will be greater than the Schnider model
(effect-site-targeting mode) in all patients except those
adults with a very low body weight.
For the Schnider model at any given height, the initial
dose increases with increasing total body weight. This
increase is modest in the normal and mildly obese patient,
to whom far less drug would be administered than with
the Marsh model. In these patients, the doses resulting
from the two different implementations of the Schnider
model are very similar. In the severely obese, the increase
in total dose is much more rapid, and can be significantly
different with the two different implementations of the
Schnider model. In particular, in young, tall, obese
patients, the fixed TTPE method will result in a greater
initial propofol dose (as a result of a slower keo value, and
thus a significantly higher peak plasma concentration for
the same effect-site target concentration).
‘Maintenance’ infusion rates
After the initial dose, the infusion rate administered by a
TCI system depends of course on the estimated rates of
redistribution and metabolism. As time passes, and the
concentrations in the different compartments equilibrate,
eventually the infusion rate gradually decreases to that
required to replace drug lost by metabolism.
As mentioned before, for the Marsh model, the fast and
slow re-distribution rate constants are proportional to the
weight of the patient, whereas for the Schnider model, the
fast re-distribution rate constant depends only on age,
whereas the slow re-distribution rate constant is independent
of age, weight, or height. In the Marsh model, the metabolic
rate constant varies with weight only, whereas in the Schnider
model it varies according to LBM and total body weight.
Figure 10 illustrates the influence of choice of model,
age, gender, weight, and height on the total propofol dose
that would be administered to patients during the period
between 15 min and 60 min after starting an infusion with
a target 5 mg ml21. The dose administered by the Marsh
model is unaffected by age or height, and is a linear func-
tion of body weight. For the Schnider model, increasing
age decreases the dose, whereas increasing height
increases the dose (except in morbidly obese patients
where shorter patients of the same weight will receive
greater doses). Except in very thin patients, increasing
weight increases the dose.
Despite these differences, for most patients the choice of
model (and effect-site targeting implementation method)
does not result in significantly different maintenance infusion
rates.
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Fig 9 Influence of total body weight, height, age, and gender on the cumulative propofol dose administered during the first 15 min at a target
concentration of 5 mg ml21. The figures illustrate the doses administered by the Marsh model in plasma targeting mode (green) and the Schnider
model in effect-site targeting mode (fixed keo method red, fixed TTPE implementation blue). The solid lines represent the doses implemented by
current infusion systems, whereas dashed lines indicate the doses that would be administered to severely obese patients if the systems did not correct
for the paradoxical decrease in LBM (see text). (A) Female age 20 yr; (B) Male 20 yr; (C) Female 40 yr; (D) Male 40 yr; (E) Female 80 yr; (F) Male
80 yr.
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Fig 10 Influence of total body weight, height, age, and gender on the cumulative ‘maintenance dose’ administered from 15 min to 60 min after
starting an infusion of propofol at a target concentration of 5 mg ml21. The figures illustrate the doses administered by the Marsh model in plasma
targeting mode (green) and the Schnider model in effect-site targeting mode (fixed keo method red, fixed TTPE method blue). The solid lines represent
the doses implemented by current infusion systems, whereas dashed lines indicate the doses that would administered to severely obese patients if the
systems did not correct for the paradoxical decrease in LBM (see text). (A) Female age 20 yr; (B) Male 20 yr; (C) Female 40 yr; (D) Male 40 yr; (E)
Female 80 yr; (F) Male 80 yr.
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Comment
With current knowledge, there is little conclusive evidence
to demonstrate the superiority of any particular model or
method of effect-site targeting implementation. In general,
it is best for anaesthetists to use the model and methods
with which they are most familiar, and to only use a differ-
ent model or method of effect-site implementation if they
understand the differences of the new model or method.
Most experts would agree that if the Schnider model is
used it should be used in effect-site targeting mode,
whereas if the Marsh model is used it should be used in
plasma targeting mode or if it is used in effect-site targeting
mode, then it should be used with the faster keo for propofol
recommended by Struys and colleagues23 (1.2 min21).
Anaesthetists using the Marsh model in the years after
TCI systems were first available quickly learnt by experi-
ence that target concentrations appropriate for younger
patients were associated with haemodynamic instability in
elderly patients. This is because of both pharmacokinetic
and pharmacodynamic changes with age. The Marsh model
does not make any adjustments for age, and has been shown
to under-predict plasma propofol concentrations in the
elderly.24 Advancing age is also associated with increased
pharmacodynamic sensitivity to the effects of propofol.
A major benefit of the Schnider model is that it adjusts
doses and infusion rates according to patient age. This pro-
vides a strong argument for using the Schnider model in
elderly and unwell patients, in whom smaller bolus doses
will be given after target increases, and this may improve
haemodynamic stability and safety.
The situation is less clear for morbidly obese patients.
The clinical experience of anaesthetists using TCI systems
is that if the total body mass of severely obese patients is
used with the Marsh model, the resulting large doses at
induction often result in adverse haemodynamic conse-
quences. This observation probably results from the fact that
the initial volume of distribution (V1) has been shown not
to be significantly increased in obesity,21 and that induction
dose requirements are more closely related to LBM.4
The problem for clinicians using the Marsh model is
that although induction requirements are more closely
related to LBM, maintenance requirements do increase sig-
nificantly with severe obesity, and are more closely related
to total body mass. As a result, for the Marsh model there
remains controversy over what value the user should input
into the TCI system for patient weight. Most anaesthetists
do not input the real total body weight with morbidly
obese patients, when using the Marsh model. Many input
a weight calculated using a formula recommended by
Servin:21 ‘Input weight’=IBM+0.4(TBW–IBM).
Albertin used this formula with the Marsh model during
TCI propofol in obese patients, with IBM calculated using
the Lemmens formula.12 Predictive accuracy was good for
the first 20 min, which is not surprising since the input
weight is generally closer to the LBM than total body
weight. For samples taken after 40 min, however,
measured blood concentrations were significantly lower
than predicted concentrations.
The problems for clinicians using the Schnider model in
obese patients relate, as indicated earlier, to the problems
with the LBM calculation, and the differences between the
two methods of effect-site targeting implementation. The
equipment manufacturers have implemented a pragmatic
solution to the problem of the paradoxical decrease in LBM
in the morbidly obese. In the severely obese, maintenance
dose requirements do increase with increasing body weight,
and the linear increase in k10 in the severe obese resulting
from the ‘fixing’ of LBM at the maximum value, seems to
be a reasonable and logical solution. Further studies are
required to provide the scientific evidence for this.
For most patients, the different methods of Schnider
effect-site targeting implemented in the Asena and Base
Primea systems result in clinically insignificant differences
in dose administered. In a very small subset of the popu-
lation, the fixed TTPE method will result in significantly
higher induction doses. This is because, in these patients,
the system will estimate larger values for k10 and k12 than
for older, shorter, thinner patients. As a result, it will esti-
mate more rapid falls in plasma concentration after a bolus
dose, which with a fixed keo results in an earlier TTPE. If
the TTPE is fixed, a slower (smaller) keo is required to
delay the TTPE, and this slower keo then results in the
requirement for a greater plasma concentration overshoot
and thus a much large initial bolus size. It is not clear at
present which method of effect-site targeting implemen-
tation is safest and most appropriate.
The studies from which the Marsh and Schnider phar-
macokinetic models were developed did not include
severely obese patients. Until there is good scientific evi-
dence showing reasonable predictive performance of either
of these, or a new pharmacokinetic model, target-
controlled infusions should be used with caution in
severely obese patients, regardless of which model or
effect-site implementation method is used.
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